Third, activation of the IL-23/IL-17 pathway was the main manifestation of bone changes in both PsA and AS, however, the anti-citrullinated protein antibody (ACPA) levels were shown to promote bone loss in RA but not in PsA and AS [15,16]. Here, PRTN3 is linked to rheumatoid arthritis.